Validating operational risk models Free night chat with hot girls without login
Examples of tumor markers include: Tumors may be evaluated with histology, which involves examination of the structure, especially the microscopic structure, of organic tissues.
Methods of detecting tumor markers include, but are not limited to: Fluorescence in Situ Hybridization (FISH) – Laboratory technique used to detect small deletions or rearrangements in chromosomes.
It can also be used to document clinical response to treatment.
Tumor markers include, but may not be limited to, alpha- fetoprotein (AFP), CA 15-3/CA 27.29, CA 19-9, CA-125, carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA).
Oncotype Dx is considered experimental and investigational for ductal carcinoma in situ (Oncotype Dx DCIS), colon cancer (Oncotype Dx Colon), prostate cancer (Oncotype Dx Prostate) and all other indications.
Mass spectrometry based proteomic profiling (eg, Veristrat, Xpresys Lung) is a multivariate serum protein test that uses mass spectrometry and proprietary algorithms to analyze proteins in an individual’s serum.
Next-generation sequence (NGS) tests use select genes to purportedly identify molecular growth drivers for improved risk stratification and targeted therapies.
Prostate Specific Antigen (PSA) is a substance produced by the prostate gland.
Levels of PSA in the blood often increase in men with prostate cancer.
This method is purportedly used for screening, diagnosis and/or monitoring of cancer cells that may otherwise require a tissue sample.